Updated just now · Live
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Bristol-Myers Squibb Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BMY.
How to read insider trading filings
Johnson & Johnson
UnitedHealth Group Incorporated
AbbVie Inc.
Merck & Co., Inc.
Eli Lilly and Company
Thermo Fisher Scientific Inc.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BMY Stock Intelligence Report. [stoxpulse.com/stocks/bmy]
Disclaimer: The information on this page about Bristol-Myers Squibb Company (BMY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Bristol-Myers Squibb Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No earnings data available.
Here's Why Bristol Myers Squibb (BMY) is a Strong ...
2h ago
Geronimo Power Announces Start of Operations at Bl...
4h ago
StoxPulse AI results for BMY: Pulse Score 51/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$120.73B
P/E Ratio
15.6
EPS
$0.53
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Geronimo Power Announces Start of Operations at Blevins Solar
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
BMY Stock: Analysts See 16% Upside and a Strong Buy
TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term